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a b s t r a c t
Radionuclide myocardial perfusion imaging (MPI) can be used to demonstrate the presence
of coronary heart disease and to risk stratify and guide management of patients with known
disease. It has the ability to localize hemodynamically important coronary stenoses, and
assess the extent and severity of coronary obstruction by the presence and extent of
perfusion defects. A normal stress MPI indicates the absence of coronary obstruction and
hence of clinically signiﬁcant disease. Cardiac PET has the advantage from SPECT of higher
spatial and temporal resolution, and a decreased radiation exposure to patients. Hybrid
cardiac imaging combining SPECT or PET with CT data appears to offer superior diagnostic
and prognostic information in patients with intermediate risk for CAD. A signiﬁcant progress
in better quantiﬁcation of myocardial blood ﬂow and coronary ﬂow reserve has recently
been seen. Also several studies have demonstrated that the combination of imaging
apoptosis and matrix metalloproteinases production can help imaging vulnerable plaque
and identifying the group of high-risk asymptomatic patients who will beneﬁt most by an
imaging procedure.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
* Correspondence to: Department of Cardiovascular Diseases, Jagiellonian University, Collegium Medicum, Hospital John Paul II, Krakow,
Poland. Tel.: +48 601820955.
E-mail address: kostkiewiczmagda@gmail.com
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/crvasa
.http://dx.doi.org/10.1016/j.crvasa.2015.09.010
0010-8650/# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved..
Funding body . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e451
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e451
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 4 4 6 – e 4 5 2 e447Introduction
The accurate noninvasive diagnosis and functional evaluation
of coronary artery disease (CAD) is an important step in
selecting the appropriate management strategy. A complete
assessment of CAD requires both anatomical and functional
information. This can be obtained in a variety of ways and the
common imaging techniques overlap in their capabilities,
particularly for the assessment of myocardial viability,
function, and coronary anatomy. Several noninvasive imaging
options are available for the assessment of suspected or
known coronary artery disease and for a long-term prognosis
of the disease. Radionuclide tests occupy a central position
within the cardiac imaging modalities, and among them
myocardial perfusion imaging (MPI) has an obvious place
because of its perfect validation for assessing myocardial
perfusion. Patients with ECG abnormalities, poor exercise
capacity, or intermediate pretest likelihood of disease accord-
ing to the ECS guidelines, would be the best candidates for this
noninvasive imaging [1].
The introduction of 201Tl myocardial perfusion imaging as
an adjunct to ECG treadmill studies in the mid-1970s has
evolved into the discipline of nuclear cardiology today [2]. MPI
provides direct assessment of myocardial perfusion and
therefore has an important role in the diagnosis of CAD in
patients presenting with chest pain and intermediate pretest
likelihood. Techniques such as SPECT and PET currently allow
evaluating occlusive coronary atherosclerosis by estimation of
myocardial perfusion as well as effects of myocardial
hypoperfusion on metabolic activity and contractile function.
An inducible perfusion abnormality indicates impaired perfu-
sion reserve, which in turn usually corresponds to epicardial
coronary obstruction.
Diagnosis and prognosis of obstructive CAD
Exercise–ECG stress testing has an established role in
assessment of patients for the detection of occlusive CAD
and with known CAD; however, the progression from ECG-
based stress testing to current SPECT and PET technologies
has led to improvements in both diagnostic efﬁcacy (sensi-
tivity and speciﬁcity for detecting CAD) and resolution
(identifying the culprit lesion for chest pain and myocardial
ischemia) [3]. An additional advantage of myocardial perfu-
sion-based stress testing over ECG-only testing is the
applicability to patients with underlying ECG abnormalities
that mask dynamic ischemic ECG changes. Nevertheless,
many patients referred for stress testing have functional
limitations from pulmonary, orthopedic, peripheral vascular
or neurologic conditions that prevent sufﬁcient physical
exercise. Ischemic ECG signals may be uninterpretable among
patients with abnormal baseline ST segment depression of>1 mm, electronic pacing, left bundle-branch block, or
preexcitation pattern. These inadequacies as well as the
limited sensitivity and speciﬁcity of ECG-based SPECT stress
test have led to the development of alternate methods of
stressors with pharmacologic agents that either simulate
exercise, such as an adrenergic agent (dobutamine), or induce
vasodilation (adenosine or dipyridamole) [4].
Myocardial uptake of a radiotracer used for MPI is a function
of both delivery of the radiotracer to the cell surface (which is
ﬂow-dependent) and subsequent extraction and retention into
the cell (which is dependent on cell membrane integrity and
viability). Intravascular radiotracer is extracted by myocardial
tissue in proportion to blood ﬂow. Thus, the same mechanisms
leading to insufﬁcient oxygen delivery and subsequent ECG-
detected myocardial ischemia on the treadmill can be
assessed directly by interrogating regional myocardial perfu-
sion. Regions of decreased myocardial uptake on SPECT and
PET can then be correlated with speciﬁc coronary artery
vascular territories and with a culprit atherosclerotic lesion
responsible for the patient's symptoms. A repeated radiotracer
injection and imaging after stress and at rest allows
differentiating between reversible and ﬁxed perfusion defects.
Reversible defects correlate with myocardial ischemia as seen
by dynamic ECG changes between resting and stress condi-
tions. If the defect size decreases from rest to stress, this
signiﬁes hypoperfused but viable myocardium (hibernation),
which predicts a high possibility for recovery of function after
revascularization [4] (Fig. 1).
The distribution of radiotracers in various regions of the LV
reﬂects the physiologic consequence of the coronary artery
vascular territories, the extent of epicardial luminal narrowing
and downstream adaptation by the resistance vessels and
collaterals. Metabolic adaptation likely represents one of the
earliest responses to myocardial ischemia, which is regulated
to protect the structural and functional integrity of the heart.
Ischemia may be transitory and reversible, or permanent and
irreversible, leading to myocardial infarction. Myocardial
ischemia may also lead to postischemic stunning, hibernation,
and preconditioning. A decrease in oxygen delivery to the
myocardium results in the downregulation of mitochondrial
oxidative metabolism and reduced contractile function target-
ing intracellular metabolic processes. Radiotracers reﬂect
changes in blood ﬂow and myocardial extraction and this
has become the basis for subsequent cardiac SPECT and later
PET tracers for perfusion imaging. For SPECT, a family of
technetium-99m (99mTc) based radiotracers was developed in
the 1990s including now 99mTc-sestamibi and 99mTc-tetrofos-
min. Despite widespread clinical use, those radiotracers are
imperfect due partly to their nonlinear myocardial extraction
at high ﬂow rates and high initial hepatic uptake, which can
make difﬁcult interpretation of defects in the inferior wall due
to adjacent photon scatter. Radiotracers that have minimal
hepatic uptake or more rapid washout are continuously under
investigation to ameliorate some of these limitations [5].
Fig. 1 – Myocardial perfusion SPECT study viewed in slices and polar maps under stress and rest. Polar maps show perfusion,
defect extent, wall thickening, and segmental scoring of perfusion defect severity. Stress perfusion defect in the apex and
majority of which significantly improves (reverses) in rest study (arrow). Masses of one or more stress defects and reversible
portions of defects are automatically tabulated, along with stress total severity score. SSS, stress scores; SRS, rest scores;
difference scores. Software – Emory Cardiac Toolbox.
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and viability in CAD include an initial rest myocardial
perfusion image with 82Rb (rubidium) or 13N ammonia
(13NH3).
82Rb is a potassium analog that has a ﬁrst-pass
extraction of 65%. A major advantage of 82Rb over 13NH3 is that
it is produced by an 82Sr/82Rb generator without the need for a
cyclotron. Then it is followed by the rest 18F-ﬂuorodeoxyglu-
cose (18F-FDG) acquisition where the patient is ﬁrst fasted for
6–12 h and then receives a glucose load or hyperinsulinemic
clamp [6]. The most widely used radiopharmaceutical to
assess viable myocardium is 18F-FDG. As a glucose analog, 18F-
FDG is transported into myocytes by the glucose transporter
and can enter metabolic glucose pathways. Increased 18F-FDG
uptake can be observed in ischemic tissue; markedly reduced
or absent uptake indicates scar formation. Normal myocardi-
um demonstrates uptake of both the perfusion and metabo-
lism radiotracer and scar demonstrates little to no uptake of
either the metabolic or perfusion tracer matched defect.
Hibernating and thus viable myocardium is detected as having
reduced perfusion and preserved metabolism mismatched
defect. Matched metabolism and perfusion defects are
unlikely to recover following revascularization depending on
the extent of left ventricular involvement [7] (Fig. 2).
There is an extensive literature evaluating the sensitivity
and speciﬁcity of SPECT myocardial perfusion imaging for
detecting CAD. For intermediate-risk patients, noninvasive
imaging has a well-established role to diagnose CAD in many
different clinical scenarios [1,5]. An analysis of 32 studies
including 4480 patients with known or suspected CAD
demonstrated mean sensitivity and speciﬁcity of 87% and
73%, respectively, for exercise myocardial SPECT for detecting
a >50% stenosis [8]. An analysis of 16 studies of patients with
known or suspected CAD including 2492 patients demonstrat-ed sensitivity and speciﬁcity of 89% and 75%, respectively, for
vasodilator stress with dipyridamole or adenosine for the
detection of a >50% stenosis SPECT myocardial perfusion
images provides important prognostic information [8]. In a
meta-analysis, including 19 studies of >39 000 patients with
an average of 2.3 years of follow-up, the event rate with a
negative SPECT MPI was 0.6% [9].
In a meta-analysis of 177 studies (108 SPECT MPI studies, 4
PET MPI studies, and 5 both PET and SPECT studies), the
sensitivity of PET was 92.6% and the speciﬁcity was 81.3%.
SPECT had a lower sensitivity at 88.3% but a similar speciﬁcity
of 75.8% [10]. Another meta-analysis also compared these 2
modalities. The sensitivities and speciﬁcities with 82Rb PET
were 90% (CI: 0.88–0.92) and 88% (CI 0.85–0.91), respectively,
whereas SPECT results were 85% [11]. Consequently, PET may
signiﬁcantly improve diagnostic accuracy compared with
SPECT. Rest and stress ejection fraction, left ventricular
volumes, and transient ischemic dilation can be assessed
with SPECT MPI. These additional data enable further
prognostication. Inclusion of left ventricular end-systolic
volume (ESV) improved risk prediction: patients with ESV
≥70 ml had more events compared with those with ESV less
than 70 ml [12].
When compared with SPECT, PET also has the advantage of
quantitative analysis of myocardial blood ﬂow and calculation
of coronary ﬂow reserve (CFR) with pharmacologic stress. With
SPECT, transient ischemic dilation of the left ventricle or
decrease in ejection fraction during stress may suggest
multivessel disease [12]. Similarly, PET with CFR may even
more accurately determine myocardium at risk. For example,
while a perfusion defect may implicate single-vessel CAD,
abnormal ﬁndings on CFR may correctly reclassify the patient
as having multivessel CAD.
Fig. 2 – PET with NH3 and 18F-FDG to assess myocardial viability. Panel a – myocardial metabolism, panel b – myocardial
perfusion. Regional myocardial 18F-FDG uptake (a) is disproportionately enhanced compared with regional myocardial blood
flow assessed by 13NH3 (b), metabolism–perfusion mismatch and is indicative of hibernating myocardium (red arrows). The
lack of 18F-FDG uptake compared with lack of regional myocardial blood flow is indicative of scar (white arrows). HLA,
horizontal long axis; VLA, vertical long axis; SA, short axis.
Reproduced with permission of G. Romanowicz, MD, PhD, Department of Nuclear Medicine, Medical University of Gdansk,
Poland.
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imaging technique for myocardial perfusion imaging and
points to some very clear advantages compared with SPECT.
PET imparts a higher speciﬁcity than SPECT, which is most
likely a consequence of its superior attenuation correction,
increased count-density images, and superior spatial resolu-
tion. Such improvements include the ability to extract
myocardial blood ﬂow reserve and coronary ﬂow reserve
measurements [13]. PET has improved spatial resolution as 2–
3 mm as compared with the 6- to 8-mm resolution of
conventional SPECT imaging [14].
MPI PET has been extensively evaluated and has been
shown to be both sensitive and speciﬁc for the diagnosis of
CAD. A meta-analysis including 14 studies (840 patients)
demonstrated a sensitivity of 0.92 (95% CI, 0.90–0.94) and
speciﬁcity of 0.85 (95% CI, 0.79–0.90) for the detection of CAD
[15].
There are multiple studies directly comparing the diagnostic
utility of PET as compared with SPECT that have demonstrated
similar or superior diagnostic accuracy for PET. On a per-patient
basis, PET had a higher diagnostic accuracy (91% versus 76%)
and higher speciﬁcity (100% versus 66%) for detection of a 50% or
greater coronary artery stenosis [16].
Stress myocardial perfusion imaging provides also strong
prognostic information with identiﬁcation of low-risk
patients. As patients typically referred for stress have an
intermediate probability of having CAD, patients with
unequivocally normal stress myocardial perfusion SPECT
studies have a <1% rate of having a risk of future cardiac
events (death or acute myocardial infarction) [17]. Similar to
SPECT, patients with a normal 82Rb PET study exhibited only
0.4% annual cardiac event rates [18]. Therefore, in diagnosingCAD, PET with analysis of myocardial blood ﬂow has the
potential to affect clinical practice in 2 important ways. First,
normal myocardial blood ﬂow may offer such a high negative
predictive value to exclude obstructive CAD that further
invasive testing is not needed, even in higher risk patients.
Second, abnormal CFR may improve classiﬁcation of ischemia
[19]. The extent and severity of myocardial ischemia and
myocardial viability can serve as useful guides for deciding
between revascularization and medical therapy. Patients
without signiﬁcant myocardial ischemia by SPECT or PET
may not beneﬁt from revascularization and would be ideally
managed with maximal medical therapy. In retrospective
studies, revascularization is associated with improved surviv-
al compared with medical therapy in patients with moderate
to severe ischemia (ischemia exceeding 10% of LV mass) [20].
Results from retrospective studies have been similar in
diabetics and in the elderly. In diabetic patients, coronary
artery bypass grafting was associated with improved survival
among patients with moderate to severe ischemia as detected
by SPECT MPI [21]. Among elderly patients without known
CAD, a beneﬁt from revascularization was observed only in
patients with ischemic myocardium ≥15% [22].
Hybrid cameras: PET/CT and SPECT/CT
Integrated SPECT/CT and PET/CT scanners are gaining
popularity as hybrid molecular imaging devices which can
acquire SPECT and CT in a single exam [23]. With the
introduction of hybrid PET/CT or SPECT/CT systems, comple-
mentary information of coronary anatomy and its physiologic
signiﬁcance on myocardial blood ﬂow reserve can be realized
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angiography, with resolution of 0.7- to 1-mm range, is suited to
provide information on the presence and extent of occlusive
CAD; PET and SPECT, on the other hand, are more suited to
determine the functional consequences of isolated or sequen-
tial anatomic lesions and the status of myocardial viability. The
combination of these anatomic and functional data is particu-
larly relevant in patients who have an intermediate ﬁnding on
either myocardial perfusion or CT angiography and has been
shown to improve sensitivity and speciﬁcity of scintigraphic
techniques. The integration of PET and multidetector CT
scanners has interesting capabilities in cardiology. This
technology enables detection and quantiﬁcation of the burden
of calciﬁed and noncalciﬁed plaques, quantiﬁcation of vascular
reactivity and endothelial health, identiﬁcation of ﬂow-limiting
coronary stenoses, and potentially, identiﬁcation of high-risk
plaques (through fusion of anatomy and biology with molecu-
larly targeted PET) in the coronary arteries in the same setting
[25]. Integrated PET/CT offers an opportunity to assess the
presence and magnitude of subclinical atherosclerotic disease
burden and to measure myocardial blood ﬂow (in ml/min/g of
myocardium) as a marker of endothelial function [26].
Myocardial perfusion imaging SPECT/CT and PET/CT facil-
itates CAD management in both the elective and the acute
settings by providing valuable information on diagnosis as
well as prognosis [17]. Stress myocardial perfusion imaging
provides strong prognostic information with identiﬁcation of
low-risk patients. As patients typically referred for stress have
an intermediate probability of having CAD, patients with
unequivocally normal stress myocardial perfusion SPECT/CT
studies have a <1% rate of having a future cardiac event (death
or acute myocardial infarction) [17]. By providing concurrent
quantitative information about myocardial perfusion and
metabolism with coronary and cardiac anatomy, PET/CT
offers the opportunity for a comprehensive noninvasive
evaluation of the consequences of atherosclerosis in the
coronary arteries and the myocardium [27].
Future directions
The current myocardial perfusion imaging toolset has limited
sensitivity for screening patients who are at risk for acute
coronary syndrome. Therefore, identiﬁcation of subclinical
coronary artery atherosclerosis to enhance primary preven-
tion of CAD, acute myocardial infarction, and sudden cardiac
death requires a paradigm shift in the perspectives of next-
generation imaging techniques. New methods to detect
endothelial dysfunction and early, preclinical atherosclerotic
plaques vulnerable to rupture are likely to play critical roles in
the realization of this new goal for cardiac stress testing.
Rather than assessing for perfusion by cardiomyocyte uptake,
radiotracers complexed with molecular markers will be used
to speciﬁcally target and to connect components of interest
within atherosclerotic lesions. The metabolic assessment of
such PET techniques coupled with anatomic assessment by CT
should allow identiﬁcation and, potentially, prediction of
vulnerable plaques in the future.
Quantitative PET ﬂow measurements have been used to
demonstrate improvement in endothelial dysfunction andmyocardial ischemia in patients with advanced CAD after
medical treatment [28]. Further studies are needed to elucidate
the role of PET-based coronary ﬂow quantiﬁcation in improv-
ing screening for preclinical CAD and the potential to guide
therapeutic decisions. Molecular imaging offers opportunities
to devote the continuously improving comprehension of the
pathophysiology of atherosclerosis at the molecular and
cellular levels for identiﬁcation of the vulnerable plaque.
There is potential for imaging unstable atherosclerotic plaques
by targeting monocyte recruitment proteins, foam cells,
matrix metalloproteinases, and apoptosis with molecular
markers that are conjugated to a PET radiotracer [29].
Mismatches between myocardial innervation and perfu-
sion are common in patients with CAD. Regional denervation
of the heart in the postischemic myocardium may persist for
15 days or longer after an ischemic event. In the postmyo-
cardial infarction setting, the territory of abnormal 123I-MIBG
tracer uptake (corresponding to sympathetic denervation)
often exceeds the ﬁnal infarct size, and such patients are at
higher risk for subsequent ventricular arrhythmias. MIBG
studies are promising in selecting heart failure patients for ICD
therapy [30].
Further understanding of CAD pathophysiology at the
molecular and cellular levels will allow radionuclide imag-
ing to evolve into a primary prevention tool by earlier
detection of atherosclerosis as well as identiﬁcation of
vulnerable plaques and adaptations in myocardial metabo-
lism. Radionuclide tracers reﬂect physiologic processes at
the cellular level. Nuclear imaging techniques will be also
suited for cardiac molecular imaging because of their
relatively high intrinsic sensitivity and excellent depth
cellular penetration [31,32].
Conclusions
Both SPECT and PET cameras capture the photons emitted by a
radiotracer and convert the information into digital data
representing the magnitude of tracer uptake and the location
of the emission in the heart. By acquiring dynamic (ECG-gated)
scintigraphic data, information on regional and global LV
function can be assessed in cinematographic mode. Thus, the
addition of myocardial perfusion imaging to ECG monitoring
during stress tests provides information about the resolution
of regional ischemia, assessment for regional wall motion
abnormalities, and myocardial viability. Clear competitive
advantages of PET over SPECT include higher spatial and
temporal resolution, reliable attenuation and scatter correc-
tion, and validated tracer kinetic models for measurement of
myocardial perfusion and metabolism. By providing concur-
rent quantitative information about myocardial perfusion
and/or metabolism with coronary and cardiac anatomy,
SPECT/CT and PET/CT offer the opportunity for a comprehen-
sive noninvasive evaluation of the consequences of athero-
sclerosis in the coronary arteries and the myocardium.
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